A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
Public ClinicalTrials.gov record NCT06799000. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Double-dummy, Placebo-controlled, Multicenter, Phase 3 Study Assessing the Efficacy, Safety, and Tolerability of 2 Doses of Remibrutinib Over a 68-week Treatment Period in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa. (RECHARGE-1)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
Study identification
- NCT ID
- NCT06799000
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 588 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years to 100 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2025 (Actual)
- Primary completion
- May 17, 2027 (Estimated)
- Completion
- Oct 4, 2027 (Estimated)
- Last update posted
- Oct 15, 2026
2025 – 2027
United States locations
- U.S. sites
- 36
- U.S. states
- 21
- U.S. cities
- 35
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Medical Dermatology Specialists | Phoenix | Arizona | 85006 | — |
| Johnson Dermatology | Fort Smith | Arkansas | 72916 | — |
| Arkansas Research Trials | North Little Rock | Arkansas | 72117 | — |
| Cheryl Effron MD Inc | Anaheim | California | 92807 | — |
| Physioseq | Sacramento | California | 95826 | — |
| Olive View UCLA Medical Center | Sylmar | California | 91342 | — |
| Clinical Trials Research Institute | Thousand Oaks | California | 91320 | — |
| Howard University College of Medicine | Washington D.C. | District of Columbia | 20060 | — |
| Florida Academic Centers Research and Education LLC | Coral Gables | Florida | 33134 | — |
| University of MiamiHealth System | Miami | Florida | 33125 | — |
| Ziaderm Research LLC | North Miami Beach | Florida | 33162 | — |
| Revival Research Institute LLC | Evans | Georgia | 30809 | — |
| Gwinnett Clinical Research Center | Snellville | Georgia | 30078 | — |
| Immunology-Rheumatology Research | Suwanee | Georgia | 30024 | — |
| Illinois Dermatology Institute | Chicago | Illinois | 60602 | — |
| Dawes Fretzin Clinical Rea Group | Indianapolis | Indiana | 46256 | — |
| Equity Medical LLC | Bowling Green | Kentucky | 42104 | — |
| Dermat. and Adv. Aesthetics | Lake Charles | Louisiana | 70605 | — |
| Michigan Center for Rsrch Company | Clarkston | Michigan | 48346 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202-2689 | — |
| Revival Research Institute | Troy | Michigan | 48084 | — |
| University of Mississippi Med Ctr | Jackson | Mississippi | 39216 | — |
| Care Access Hoboken | Hoboken | New Jersey | 07030 | — |
| Forest Hills Dermatology Group | New York | New York | 10003 | — |
| Icahn School Of Med At Mount Sinai | New York | New York | 10029 | — |
| Skinsearch of Rochester Inc | Rochester | New York | 14623 | — |
| OnSite Clinical Solutions LLC | Huntersville | North Carolina | 28078 | — |
| Wake Forest Baptist Health | Winston-Salem | North Carolina | 27104 | — |
| Unity Clinical Research | Oklahoma City | Oklahoma | 73118 | — |
| Essential Medical Research | Tulsa | Oklahoma | 74137 | — |
| UP Medical Center H System | Pittsburgh | Pennsylvania | 15213-3403 | — |
| Medical University of South Carolina MUSC | Charleston | South Carolina | 29425 | — |
| Advanced Research Experts | Nashville | Tennessee | 37211 | — |
| Bellaire Dermatology Associates | Bellaire | Texas | 77401 | — |
| RFSA Dermatology | San Antonio | Texas | 78213 | — |
| Virginia Clinical Research | Norfolk | Virginia | 23507 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 103 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06799000, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 15, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06799000 live on ClinicalTrials.gov.